TRELSTAR - I’m Interested in Using TRELSTAR

I’m Interested in Using TRELSTAR
You may have already discussed with your doctor the various treatment options available for your prostate cancer. TRELSTAR is one option available to you.

TRELSTAR is a type of prescription drug known as an LHRH agonist, used for the management of advanced prostate cancer. It is administered by injection (a shot) in your doctor’s office by a doctor or nurse. TRELSTAR is injected into the muscle of your buttocks. You have two different formulations to choose from with TRELSTAR. TRELSTAR Depot (3.75 mg) is given as an intramuscular injection once every 4 weeks. TRELSTAR LA (11.25 mg) is given as an intramuscular injection once every 12 weeks. Your doctor will work with you in determining the type of formulation that is right for you.

It is important that you learn as much as you can and work with your doctor to best manage your prostate cancer care. If you and your doctor determine that TRELSTAR is a treatment option for you at this time, there are a number of valuable sections in this site that will help you understand your condition and what to expect.

It may comfort you at this time to know that you are not alone. As of 2005 it is estimated that over 2 million American men are living with prostate cancer. There are many support groups and resources available that can assist you.

Your healthcare provider is your best source for information and care. Work with your doctor in developing or maintaining a treatment program that is right for you.

Indications and Usage
TRELSTAR^® Depot and TRELSTAR^® LA are indicated in the palliative treatment of advanced prostate cancer. TRELSTAR Depot or TRELSTAR LA offer an alternative treatment for prostate cancer when orchiectomy or estrogen administration are either not indicated or unacceptable to the patient.

Safety Information

The most commonly reported adverse events associated with the use of TRELSTAR^® Depot/TRELSTAR^® LA included hot flushes (58.6%/73.0%), skeletal pain (12.1%/13.2%), impotence (7.1%/2.3%), headache (5.0%/6.9%), leg pain (2.1%/5.2%), and edema in legs (0.0%/6.3%) . TRELSTAR is contraindicated in women who are or may become pregnant as well as patients who are hypersensitive to triptorelin, other LHRH agonists, or LHRH . Infrequent postmarketing reports of anaphylactic shock and angioedema have been received since 1986 (global experience) . As with all LHRH agonists, triptorelin causes an initial transient increase in testosterone levels. Patients may experience the onset or exacerbation of symptoms during this period, including bone pain, neuropathy, hematuria, spinal cord compression, or urethral or bladder outlet obstruction. Patients with metastatic vertebral lesions and/or urinary tract obstruction should be closely observed.